Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial
Lancet (London, England), 2026
Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study
The Lancet regional health. Europe, 2026;67:101738
GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) – beyond weight loss: a condensed scientific review
Drugs in context, 2026;15
Plant-Based Nutrition Alleviates Gastrointestinal Symptoms and Enhances Protein Intake during GLP-1 Therapy
Current developments in nutrition, 2026;10(7):109393
Weight Drop-Foot Drop: A Case Series of Peroneal Nerve Palsy from Leg Crossing after Tirzepatide-Mediated Weight Loss
Case reports in neurology, 2026;18(1):364-369
The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer’s Disease
Acta naturae;17(4):110-120
Glycyl-l-histidyl-l-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro
Metallomics : integrated biometal science;16(5)
Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis
Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026
GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults
Annals of oncology : official journal of the European Society for Medical Oncology, 2026
Use of Glucagon-Like Peptide-1 Receptor Agonists in Danish Adolescents and Young Adults 2018-2025
Obesity (Silver Spring, Md.), 2026
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study
The lancet. Diabetes & endocrinology, 2026
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
The lancet. Diabetes & endocrinology, 2026
Cagrilintide-semaglutide: a new option for patients with type 2 diabetes
The lancet. Diabetes & endocrinology, 2026
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Lancet (London, England), 2026
Effects of Semaglutide on Cardiometabolic Risk in People with Obesity, With and Without Type 2 Diabetes: A Retrospective Observational Study
Journal of clinical medicine, 2026;15(12)
Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples
Journal of mass spectrometry : JMS;59(1):e4996
CCN5 suppresses injury-induced vascular restenosis by inhibiting smooth muscle cell proliferation and facilitating endothelial repair via thymosin β4 and Cd9 pathway
European heart journal;46(17):1645-1658
Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing
Investigative ophthalmology & visual science;66(14):31
Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion
Cardiovascular research;121(17):2747-2758
Thymosin β4 released by mast cells under stress conditions impairs intestinal epithelial barrier via IL22RA1/JAK1/STAT3 signaling in irritable bowel syndrome
World journal of gastroenterology;31(42):111706